CAPR - NASDAQ

Capricor Therapeutics, Inc.

Capricor Therapeutics, Inc.

CAPR·NASDAQ

$27.64

+1.1%
HealthcareBiotechnology

Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of spectrum of diseases and disorders. Its lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase III clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD); and CAP-1002, which is in Phase II clinical trial for the treatment of cytokine storm associated with SARS-CoV-2. The company also develops CAP-2003 that is in pre-clinical development for the treatment of trauma related injuries and conditions; and two vaccine candidates, which are in development stage for the potential prevention of COVID-19. It collaborates with Lonza Houston, Inc. for the clinical manufacturing of CAP-1002, its cell therapy candidate for the treatment of DMD and other indications. The company was founded in 2005 and is headquartered in San Diego, California.

StatementsValue Model

At a Glance

Live Snapshot
Market Cap$1.26B
EPS-2.2600
P/E Ratio-12.23
Earnings Date08/11/2026

Earnings Call Transcript

CAPR • 2025 • Q2

Operator
Good afternoon, ladies and gentlemen, and welcome to the Capricor Therapeutics Second Quarter 2025 Conference Call. [Operator Instructions] This call is being recorded on Monday, August 11, 2025. I would now like to turn the conference over to CFO, A.J. Bergmann, for the forward-looking statements. Please go ahead.
Operator
[Operator Instructions] Your first question comes from Ted Tenthoff from Piper Sandler.
Operator
Your next question comes from Leland Gershell from Oppenheimer.
Operator
The next question comes from Joe Pantginis from H.C. Wainwright.
Joseph Pantginis
Got it. Looking forward to more visibility out of the program and good luck with the meeting this week.
Operator
Your next question comes from Kristen Kluska from Cantor.
Operator
Your next question comes from Madison El-Saadi from B. Riley Securities.
Operator
Your next question comes from Aydin Huseynov from Ladenburg Thalmann.
Operator
Your next question comes from Boobalan Pachaiyappan from ROTH Capital.
Operator
Your next question comes from Catherine Novack from Jones.
Catherine Clare Novack
Got it. And then the R&D expense for 2Q, what accounts for the increase? Is this buildup of product inventory ahead of potential launch? Or is this due to ongoing clinical studies that we should expect to see continued growth on that line?
Anthony J. Bergmann
Yes. Thanks, Catherine. I mean -- it encompasses a little bit of both of what you said. We're obviously in the end stages of HOPE-3, but those patients, 104 of them are ongoing in that clinical development expense line item. We're also obviously preparing for the CMC endeavor. So that's where it's at. Obviously, when we get more clarity and feedback from FDA and announce more plans, I think we'll have more granular items on the burn rate moving forward. But it really encapsulates both of those areas. That's the main areas of spend.
Operator
[Operator Instructions] Your next question comes from Matthew Venezia from AGP.
Matthew J Venezia
Got it. And just a little bit on the run rate. Do you expect it to taper off in 2026 once you kind of get clarity regulatory-wise and potential launch-wise as HOPE-3 winds down and should R&D come down and maybe G&A go up a little bit?
Anthony J. Bergmann
Yes, I think that's fair. Thanks, Matt. I mean, obviously, again, as I articulated, the next steps in HOPE-3 is a big aspect to that. But should we achieve approval, we'll have some pretty serious capital injections around the potential sale of the PRV and $80 million from Nippon Shinyaku. That will allow us, of course, to invest in CMC expansion and everything we want to do around the launch for commercial endeavors. So that's kind of how we're looking at it. Obviously, more granular level can be discussed in the future, but we expect the capital to go right where it needs to be, which is preparing for the launch.
Operator
Your next question comes from Chris Lemos from [indiscernible].
Transcript from August 18, 2025

Other Transcripts

 

capr Earnings Call Transcripts

CAPR
View Financials All Transcripts

Related Guides

Blog Categories

Continue your CAPR research with focused valuation guides.

Forecasting

Compare management guidance with modeled outcomes.

Risk Analysis

Track estimate risk, misses, and downside scenarios.

Reference

Review analyst process and transcript interpretation.

Value Investing

Anchor quarterly narrative to intrinsic value discipline.

Research Paths

Pick your next lens
1

Snapshot

Start with context, operating signals, and key market metrics.

2

Value Model

Stress test fair value across bear, base, and bull assumptions.

3

Statements

Validate revenue quality, margins, and balance sheet durability.

4

Earnings Call

Read management commentary and compare it with reported outcomes.

5

Dividends

Check payout sustainability and long-term distribution behavior.

6

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.